Trabeculectomy and MMC a success at nine years

Article

In eyes with primary open angle glaucoma (POAG), trabeculectomy with low dosage mitomycin-C (MMC) and intensified postoperative management offers an increased success rate and a lower incidence of complications, according to Professor Alfredo Reibaldi of the University of Catania, Italy.

In eyes with primary open angle glaucoma (POAG), trabeculectomy with low dosage mitomycin-C (MMC) and intensified postoperative management offers an increased success rate and a lower incidence of complications, according to Professor Alfredo Reibaldi of the University of Catania, Italy.

Patients with POAG, uncontrolled by therapy, who took part in a prospective, randomized, double-blind clinical trial between 1995 and 1999 were reviewed. Subjects originally underwent a trabeculectomy with MMC or saline solution and cases with >9 years follow-up were considered for review.

Of the 133 eyes included in the study, 94 had a >9 years follow-up (57 treated with MMC and 37 with placebo). An IOP of <14 mmHg was found in 47 and 17 eyes, respectively, six and 11 eyes, respectively were taking medical therapy, while four and nine eyes had undergone a re-operation. Glaucomatous visual field progression was noted in five and 16 eyes however, no significant difference was seen in incidence of cataract and other complications.

These nine-year results suggest that trabeculectomy with MMC and intensive postoperative management can significantly improve success rates and decrease the incidence of complications.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.